|
Synonyms: FE 999301 | FE-301 | FE-999301 | TJ301
Compound class:
Peptide or derivative
Comment: Olamkicept is a recombinant protein that fuses the extracellular domain of the signal transducing subunit of the IL-6 receptor, IL-6Rβ (glycoprotein 130, gp130), to a human IgG Fc fragment [3]. The full construct is a dimer of covalently linked identical peptide chains. Mechanistically olamkicept acts as an inhibitor of the IL-6 signalling pathway. Olamkicept inhibits trans signalling by the soluble IL-6 receptor (sIL-6R) [1], a mechanism that is involved in human inflammatory and autoimmune diseases [2]. It is hypothesised to be clinically effective in reducing disease signs and symptoms whilst not being detrimental to the role of IL-6 in the acute immune response to infection.
|
| References |
|
1. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C et al.. (2000)
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med, 6 (5): 583-8. [PMID:10802717] |
|
2. Kallen KJ. (2002)
The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta, 1592 (3): 323-43. [PMID:12421676] |
|
3. Rose-John S, Conaris Research Institute AG. (2001)
Fusion proteins comprising two soluble gp130 molecules. Patent number: EP1148065. Assignee: Conaris Research Institute AG. Priority date: 21/04/2000. Publication date: 24/10/2001. |
